Dere, Willard Honglen, MD, FACP

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Professor
  • Divisions: Endocrinology and Metabolism

Board Certification

  • American Board of Internal Medicine

Academic Office Information

  • George and Dolores Eccles Institute of Human Genetics
    15 N 2030 E, Room: 2160
    Salt Lake City, UT 84112

Academic Bio

Dr. Dere has extensive experience in clinical research during his 25 year stint in the biopharmaceutical industry. The experience was complemented by substantive regulatory and drug safety experience during that time. At the University of Utah, Dr. Dere serves as the Executive Director of the Program in Personalized Health and Co-Director of the Utah Center for Clinical and Translational Science..

While at Eli Lilly from 1989 to 2003, he conducted several clinical pharmacology Phase 1 studies with nasal insulin, several oral antibiotics, and PTH 1-34. He later served as executive director of the clinical pharmacology and the therapeutic areas charged with developing appropriate biomarkers, and proof-of-concept trials in several therapeutic areas. During this time, he supervised the clinical teams responsible for the development of the medicines duloxetine and atomoxetine. His phase 2 and 3 experiences were focused in endocrinology. He led the phase 2 and 3 programs for raloxifene, both in postmenopausal osteoporosis and breast cancer prevention, and PTH 1-34 in postmenopausal osteoporosis and glucocorticoid-induced osteoporosis. Hallmarks of these programs were the large fracture outcomes trials‹raloxifene (MORE) published in JAMA and PTH 1-34, published in the NEJM. From 2003 to 2014 at Amgen, Dr. Dere led the development programs of multiple medicines including denosumab marketed for both postmenopausal osteoporosis and prevention of deleterious skeletal outcomes from metastatic cancers; romiplostim for immune thrombocytopenic purpura; panitumumab for colorectal cancer; and cinacalcet for secondary hyperparathyroidism in end-stage renal disease. These programs involved extensive evaluation in both phase 2 and phase 3 clinical trials which occurred both in United States and non-American clinical trial sites, and the individual trials were published in prestigous biomedical journals.

Additionally, Dr. Dere was director of the Lilly European Regulatory and Safety department based in UK from 1991-1994, and a member of the CIOMS 3 Pharmacovigilance Working Group, sponsored by the World Health Organization. He has participated in a number of regulatory hearings at both the FDA and European Medicine Agency for approvals of oral antibiotics; raloxifene and PTH 1-34 in osteoporosis; and panitumumab for colorectal cancer. He has actively participated in a number of publications authored by academic, industry, and regulatory personnel which have served as the basis for subsequent guidelines for the European Medicines Agency.

Research Statement

Dr. Dere has extensive experience in clinical research during his 25 year stint in the biopharmaceutical industry. The experience was complemented by substantive regulatory and drug safety experience during that time. At the University of Utah, Dr. Dere serves as the Executive Director of the Program in Personalized Health and Co-Director of the Utah Center for Clinical and Translational Science.

While at Eli Lilly from 1989 to 2003, he conducted several clinical pharmacology Phase 1 studies with nasal insulin, several oral antibiotics, and PTH 1-34. He later served as executive director of the clinical pharmacology and the therapeutic areas charged with developing appropriate biomarkers, and proof-of-concept trials in several therapeutic areas. During this time, he supervised the clinical teams responsible for the development of the medicines duloxetine and atomoxetine. His phase 2 and 3 experiences were focused in endocrinology. He led the phase 2 and 3 programs for raloxifene, both in postmenopausal osteoporosis and breast cancer prevention, and PTH 1-34 in postmenopausal osteoporosis and glucocorticoid-induced osteoporosis. Hallmarks of these programs were the large fracture outcomes trials‹raloxifene (MORE) published in JAMA and PTH 1-34, published in the NEJM. From 2003 to 2014 at Amgen, Dr. Dere led the development programs of multiple medicines including denosumab marketed for both postmenopausal osteoporosis and prevention of deleterious skeletal outcomes from metastatic cancers; romiplostim for immune thrombocytopenic purpura; panitumumab for colorectal cancer; and cinacalcet for secondary hyperparathyroidism in end-stage renal disease. These programs involved extensive evaluation in both phase 2 and phase 3 clinical trials which occurred both in United States and non-American clinical trial sites, and the individual trials were published in prestigous biomedical journals.

Additionally, Dr. Dere was director of the Lilly European Regulatory and Safety department based in UK from 1991-1994, and a member of the CIOMS 3 Pharmacovigilance Working Group, sponsored by the World Health Organization. He has participated in a number of regulatory hearings at both the FDA and European Medicine Agency for approvals of oral antibiotics; raloxifene and PTH 1-34 in osteoporosis; and panitumumab for colorectal cancer. He has actively participated in a number of publications authored by academic, industry, and regulatory personnel which have served as the basis for subsequent guidelines for the European Medicines Agency.

Education History

Type School Degree
Postdoctoral Training University of California, San Francisco
Endocrinology and Metabolism
Postdoctoral Training
Residency University of Utah
Internal Medicine
Resident
Internship University of Utah
Internal Medicine
Intern
Professional Medical University of California, Davis
Medicine
M.D.
Undergraduate University of California, Davis
History, Zoology
B.A.

Selected Publications

Journal Article

  1. Cooper C, Bardin T, Brandi ML, Cacoub P, Caminis J, Civitelli R, Cutolo M, Dere W, Devogelaer JP, Diez-Perez A, Einhorn TA, Emonts P, Ethgen O, Kanis JA, Kaufman JM, Kvien TK, Lems WF, McCloskey E, Miossec P, Reiter S, Ringe J, Rizzoli R, Saag K, Reginster JY (2016 Feb). Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clin Exp Res, 28(1), 1-16.
  2. Brandi M, Abadie E, Daly A, Dere W, et al (). Challenges faced in the integration of pharmacogenetics/genomics into drug development. J Pharmacogenomics Pharmacoproteomics, 3, 108.
  3. Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Dere WH, Durez P, Matucci-Cerinic M, Flamion B, Laslop A, Lekkerkerker FJ, Miossec P, Mitlak BH, Ormarsdottir S, Paolozzi L, Rao R, Reiter S, Tsouderos Y, Reginster JY (2011 Feb). Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Curr Med Res Opin, 27(2), 315-25.
  4. Dere WH, Suto TS (2009 Jan). The role of pharmacogenetics and pharmacogenomics in improving translational medicine. Clin Cases Miner Bone Metab, 6(1), 13-6.
  5. Goldhahn J, Mitlak B, Aspenberg P, Abadie, E, Augat P, Brandi ML, Burlet N, Chines A, Delmas P, Dere W, etal (). Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair. J Bone Joint Surg Am, 90(Supp. 1), 43-47.
  6. Dere WH, et al (). Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America. Drug Inf J, 41(1), 31-46.
  7. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (). Clinical use of bone mineral density measurement with other risk factors in osteoporosis. Progress in Osteoarthrology, 11, 92-101.
  8. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000). Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int, 11(2), 120-7.
  9. Dere WH (). Clinical safety of raloxifene. Postgrad Med, 23-27.
  10. Huster W, Shah A, Kaiser G, Dere W, DiMarchi R (). Statistical and operational issues arising in an interim analysis when the study will continue. Drug Inf J, 33, 869-875.
  11. Dere WH (1998 Apr). Clinical efficacy of SERMs. Aging (Milano), 10(2), 160-1.
  12. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998). Lifetime risk of hip fractures is underestimated. Osteoporos Int, 8(6), 599-603.
  13. Brumfitt W, Hamilton-Miller J, Dere W, Voi M (). Cefaclor Advanced Formulation at 'High Dosage' versus Cefaclor for Treatment of Lower Respiratory Tract Infections. J Chemother, 5(Supp. 1), 320-321.
  14. Brumfitt W, Hamilton-Miller J, Dere W, Voi M (). Cefaclor Advanced Formulation versus Cefaclor for the Treatment of Bronchitis. J Chemother, 5(Supp. 1), 318-319.
  15. Brumfitt W, Hamilton-Miller J, Dere W, Voi M (). Cefaclor Advanced Formulation versus Cefaclor in Streptococcal Pharyngitis/Tonsillitis. J Chemother, 5(Supp. 1), 317-318.
  16. Dere WH, Therasse D (). Tolerance and Safety Profile of Loracarbef. J Chemother, 5(Supp. 1), 72-73.
  17. Alanis A, Longest KA, Senetar JE, Dere WH (1992). A multicentre trial of cefaclor advanced formulation versus cefaclor in the treatment of acute bronchitis. Postgrad Med J, 68 Suppl 3, S24-8, discussion S29.
  18. Derriennic M, Voi M, Thoren LM, Black SA, Dere WH (1992). Cefaclor AF in the treatment of streptococcal pharyngitis/tonsillitis. Postgrad Med J, 68 Suppl 3, S43-6; discussion S46-8.
  19. Hamilton-Miller JM, Iravani A, Brumfitt W, Byers KS, Dere WH (1992). Comparative trials of cefaclor AF in uncomplicated cystitis and asymptomatic bacteriuria. Postgrad Med J, 68 Suppl 3, S60-6; discussion S66-7.
  20. Stotka JL, Senetar JE, Therasse DG, Dere WH (1992). Comprehensive safety profile of cefaclor AF in respiratory, urinary tract and skin infections. Postgrad Med J, 68 Suppl 3, S73-7; discussion S78-80.
  21. Dere WH, Farlow D, Therasse DG, Ruoff GE (1992 Jan-Feb). Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis. Clin Ther, 14(1), 41-53.
  22. Dere WH, Farlow D, Therasse DG, Jacobson KD, Guerra FJ (1992 Mar-Apr). Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis. Clin Ther, 14(2), 166-77.
  23. Schupbach CW, Olovich KG, Dere WH (1992 May-Jun). Efficacy of cefaclor AF in the treatment of skin and skin-structure infections. Clin Ther, 14(3), 470-9.
  24. Casali L, Voi M, Janssen CJ, Olovich KG, Dere WH (1992 Jul-Aug). Cefaclor advanced formulation versus cefaclor in the treatment of pneumonia. Clin Ther, 14(4), 570-7.
  25. Dere WH, Groggel GC (). Diabetic Nephropathy in Patients with Non-Insulin Dependent Diabetes Mellitus. Geriatrics, 45, 48-56.
  26. Dere WH, Stults BM, Burt RW (). Cancer Prevention. Med Rounds, 2, 285-295.
  27. Stults BM, Dere WH, Caine TH (). Anticoagulation for Outpatients. West J Med, 151, 414-429.
  28. Rapoport B, Damante G, Dere W, Filetti S (1987). Studies on the promoter region of the c-Ha-ras oncogene. Horm Metab Res Suppl, 17, 57-62.
  29. Hirayu H, Dere WH, Rapoport B (1987 Mar). Initiation of normal thyroid cells in primary culture associated with enhanced c-myc messenger ribonucleic acid levels. Endocrinology, 120(3), 924-8.
  30. Membreno L, Irony I, Dere W, Klein R, Biglieri EG, Cobb E (1987 Sep). Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab, 65(3), 482-7.
  31. Mendel CM, Klein RF, Chappell D, Dere WH, Gertz BJ, Karam JH, Lavin T, Grunfeld C (). A Double-blind Placebo-controlled Crossover Trial of Amitriptyline and Fluphenazine in the Treatment of Painful Diabetic Neuropathy. J Am Med Assoc, 255, 637-639.
  32. Mendel CM, Klein RF, Chappell DA, Dere WH, Gertz BJ, Karam JH, Lavin TN, Grunfeld C (1986 Feb 7). A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. JAMA, 255(5), 637-9.
  33. Dere WH, Hirayu H, Rapoport B (1986 Feb 17). Thyrotropin and cyclic AMP regulation of ras proto-oncogene expression in cultured thyroid cells. FEBS Lett, 196(2), 305-8.
  34. Dere WH, Rapoport B (1986 Mar). Control of growth in cultured rat thyroid cells. Mol Cell Endocrinol, 44(3), 195-9.
  35. Dere WH, Hirayu H, Rapoport B (1985 Nov). TSH and cAMP enhance expression of the myc proto-oncogene in cultured thyroid cells. Endocrinology, 117(5), 2249-51.

Review

  1. Kaufman JM, Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, McCloskey E, Mitlak B, Orwoll E, Ringe JD, Weryha G, Rizzoli R (2013 Mar). Treatment of osteoporosis in men. [Review]. Bone, 53(1), 134-44.
  2. Cooper C, Fielding R, Visser M, van Loon LJ, Rolland Y, Orwoll E, Reid K, Boonen S, Dere W, Epstein S, Mitlak B, Tsouderos Y, Sayer AA, Rizzoli R, Reginster JY, Kanis JA (2013 Sep). Tools in the assessment of sarcopenia. [Review]. Calcif Tissue Int, 93(3), 201-10.
  3. Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, Sieber CC, Kaufman JM, Abellan van Kan G, Boonen S, Adachi J, Mitlak B, Tsouderos Y, Rolland Y, Reginster JY (2012 Jul). Frailty and sarcopenia: definitions and outcome parameters. [Review]. Osteoporos Int, 23(7), 1839-48.
  4. Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, Laslop A, Mitlak B, Papapoulos S, Ralston S, Reiter S, Werhya G, Reginster JY (2012 Oct). Management of glucocorticoid-induced osteoporosis. [Review]. Calcif Tissue Int, 91(4), 225-43.
  5. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdottir S, Rao R, Tsouderos Y, Reginster JY (2011 Oct). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. [Review]. Ann Rheum Dis, 70(10), 1713-8.
  6. Abadie EC, Devogealer JP, Ringe JD, Ethgen DJ, Bouvenot GM, Kreutz G, Laslop A, Orloff JJ, Vanderauwera PM, Delmas PD, Dere WH, Branco J, Altman RD, Avouac BP, Menkes CJ, Vanhaelst L, Mitlak BH, Tsouderos Y, Reginster JY (2005 Aug). Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. [Review]. Semin Arthritis Rheum, 35(1), 1-4.
  7. Hockett RD, Kirkwood SC, Mitlak BH, Dere WH (2002 Jun). Pharmacogenomics in endocrinology. [Review]. J Clin Endocrinol Metab, 87(6), 2495-9.
  8. Bryant HU, Dere WH (1998 Jan). Selective estrogen receptor modulators: an alternative to hormone replacement therapy. [Review]. Proc Soc Exp Biol Med, 217(1), 45-52.
  9. Dere W, Avouac B, Boers M, Buxton M, Christiansen C, Dawson A, Gennari C, Guillemin F, Lawaetz H, Ornskov F, Roumagnac I, Reginster JY (1998 Aug). Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. [Review]. Calcif Tissue Int, 63(2), 93-7.
  10. Dere WH (1992 Jun 22). Acute bronchitis: results of U.S. and European trials of antibiotic therapy. [Review]. Am J Med, 92(6A), 53S-57S.
  11. Dere WH, Groggel GC (1990 Jul). Update on diabetic nephropathy in NIDDM. [Review]. Geriatrics, 45(7), 48-52, 55-6.
  12. Stults BM, Dere WH, Caine TH (1989 Oct). Long-term anticoagulation. Indications and management. [Review]. West J Med, 151(4), 414-29.

Edited Book

  1. Brumfitt W, Dere WH, Hamilton-Miller JMT, Hoffbrand BI (Eds.) (). Advances in Antimicrobial Therapy: Extended Release Cefaclor AF. (Supplement 3). (Vol. 68). Postgraduate Medical Journal.
  2. Dere WH (Ed.) (). Practical Care of the Ambulatory Patient. Philadelphia: W.B. Saunders.

Book Chapter

  1. Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Montrose C, Moore RA, Weidner JR, Sittampalam GS (2004). HTS Assay ValidationBTI - Assay Guidance Manual. Bethesda (MD).
  2. Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Iversen PW, Kahl SD, Moore RA, Sawyer BD, Weidner J (2004). Assay Operations for SAR SupportBTI - Assay Guidance Manual. Bethesda (MD).
  3. Kanis JA, Johnell O, Oden A, Jnsson B, Dawson A, Muchmore D, Dere W (). The combination of low bone mineral density measurement and other risk factors in Osteoporosis. In Aso T, Yanaihara T, Fujimoto S (Eds.), The Menopause at the Millenium (pp. 352-358). New York and London: Parthenon Publishing Group.
  4. Dere WH, Burt RW, Stults BM (). Chapter 44: Cancer Prevention in Primary Care. In Stults BM, Dere WH (Eds.), Practical Care of the Ambulatory Patient (pp. 436-445). Philadelphia: WB Saunders.
  5. Stults BM, Dere WH, Caine TH (). Chapter 33: Anticoagulation in Outpatients. In Stults BM, Dere WH (Eds.), Practical Care of the Ambulatory Patient (pp. 307-330). Philadelphia: WB Saunders.

Conference Proceedings

  1. Goldhahn J, Feron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W, Mitlak B, Tsouderos Y, Boonen S (2012 May). Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int, United States, 90(5), 343-53.
  2. Bruyere O, Kanis JA, Ibar-Abadie ME, Alsayed N, Brandi ML, Burlet N, Cahall DL, Chines A, Devogelaer JP, Dere W, Goel N, Hughes N, Kaufman JM, Korte S, Mitlak BH, Niese D, Rizzoli R, Rovati LC, Reginster JY (2010 May). The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporos Int, England, 21(5), 713-22.
  3. Compston J, Reid DM, Boisdron J, Brandi ML, Burlet N, Cahall D, Delmas PD, Dere W, Devogelaer JP, Fitzpatrick LA, Flamion B, Goel N, Korte S, Laslop A, Mitlak B, Ormarsdottir S, Ringe J, Rizzoli R, Tsouderos Y, Van Staa T, Reginster JY (2008 Sep). Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int, England, 19(9), 1247-50.
  4. Dere WH (). To what extent will outcomes data become an essential part of the regulatory package for submission in the future and what are the implications of this happening? Successfully Measuring and Managing Outcomes, London: IIR Communications.
  5. Thompson WL, Hizer RE, Dere WH, Saxberg Bo EH (). Health Informatics for Cost-effective Quality-Speed Research and Regulation to Enhance Public Health. Managing the Creation of Global Electronic Submissions, Advanstar Communications.
  6. Dere WH (). One Global Clinical Protocol. EC and International Harmonization, Paris: Andre Rey Consultants.
  7. Dere WH (). International Conference on Harmonization--1: Efficacy. EC and International Harmonization, Paris: Andre Rey Consultants.

Editorial

  1. Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B (2006 Jan). Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int, 17(1), 1-7.

Abstract

  1. Brumfitt W, Hamilton-Miller J, Dere W, Voi M (). Cefaclor Advanced Formulation versus Cefaclor for the Treatment of Bronchitis [Abstract]. 8th Mediterranean Congress of Chemotherapy, Abstract 86.
  2. Brumfitt W, Hamilton-Miller J, Dere W, Voi M (). Cefaclor Advanced Formulation versus Cefaclor in Streptococcal Pharyngitis/Tonsillitis [Abstract]. 8th Mediterranean Congress of Chemotherapy, Abstract 84.
  3. Dere W, Ruoff G (). Loracarbef versus Ceclor in the Treatment of Acute Bronchitis [Abstract]. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy.
  4. Beck A, Wood J, Dere W, Rothstein G (). Anemia in the Elderly: Evidence of a Stem Cell Defect [Abstract]. Annual Meeting of the Gerontology Society of America.
  5. Stults BM, Dere WH (). Serial Impedance Plethysmography for Diagnosis of Symptomatic Venous Thrombosis [Abstract]. New England Journal of Medicine, 315, 765.
  6. Hirayu H, Dere W, Rapoport B (). Enhanced C-MYC Oncogene Expression During the Initiation of Primary Culture of Normal Thyroid Follicular Cells [Abstract]. Abstracts of the Annual Endocrine Society Meetings.
  7. Dere WH, Rapoport B (). TSH Control of the Expression of the MYC Proto-Oncogene in Cultured Thyroid Cells [Abstract]. Abstracts of the Ninth International Thyroid Congress.
  8. Dere WH, Klein R, Biglieri EG (). Focal adrenocortical steroid defects acquired in AIDS [Abstract]. Program of the Endocrine Society, 67th Annual Meeting, Abstract 543, 136.
  9. West CD, Thorne JL, Dere WH, Chavre JH (). Are Adrenal Steroids Involved in the Pathogenesis of Coronary Atherosclerosis [Abstract]. Clinical Research, 30(2), 549A.
  10. West CD, Thorne JL, Dere WH, Chavre VJ (). Adrenal Steroid Abnormalities in Diabetic and Non-Diabetic Patients with Coronary Atherosclerosis [Abstract]. Clinical Research, 30(1), 91A.

Other

  1. Dere WH (). Denosumab Case Study. Molecular Medicines of Ireland, e-teaching module. Clinical and Translational Research Training Programme.
  2. Dere WH (). Registration of new drugs for osteoporosis. Advanced Training Course on Osteoporosis (pp. 148-157). International Osteoporosis Foundation.
  3. Dere WH (). Pharmacoeconomics studies in osteoporosis. Advanced Training Course on Osteoporosis (pp. 130-134). International Osteoporosis Foundation.
  4. Dere WH (). Registration of new drugs for osteoporosis. Advanced Training Course on Osteoporosis (pp. 148-157). European Foundation for Osteoporosis and Bone Disease.
  5. Dere WH (). Pharmacoeconomics studies in osteoporosis. Advanced Training Course on Osteoporosis (pp. 130-134). European Foundation for Osteoporosis and Bone Disease.
  6. Dere WH (). Selected aspects of registration and health economics for osteoporosis trials. Training Course on Osteoporosis (pp. 147-153). European Foundation for Osteoporosis and Bone Disease.
  7. Dere WH (). The Core Safety Data Sheet: Standards for Good Clinical Safety Labeling Practices. CIOMS III Working Group. World Health Organization.
  8. Dere W (). Registration of new drugs for osteoporosis. Training Course on Osteoporosis (pp. 129-133). European Foundation for Osteoporosis and Bone Disease.
  9. Dere WH (). Endocrinology and Metabolism Knowledge Base Section. Iliad: A Medical Expert System. Salt Lake City, UT: Applied Informatics.

News

Video